A bio-tech company based out of the Purdue Research Park has developed a potential game changer in identifying ovarian cancer. The FDA has approved the use of On Target Laboratories’ fluorescent imaging agent CYTALUX to target cancer during surgery. We get details from On Target Laboratories Chief Science Officer & Founder Dr. Philip Low.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}